Vaxart Inc Stock Price, News & Analysis

Vaxart, Inc. (Nasdaq: VXRT) announced successful results from a Phase 1b clinical trial showing that its oral norovirus vaccine boosted immune responses in subjects previously vaccinated over a year ago. The study involved 12 participants and demonstrated that both previously vaccinated and unvaccinated individuals showed similar immune responses after receiving a booster dose. Vaxart's CEO emphasized the significance of these findings for developing repeatable oral vaccines for seasonal diseases. The trial results may differentiate Vaxart's vaccines from traditional injectable options.

Vaxart, Inc. (Nasdaq: VXRT) has entered into an exclusive licensing agreement with Altesa Biosciences for Vapendavir, an antiviral targeting enteroviruses. Vaxart can earn up to $130 million in milestone payments and royalties from Vapendavir sales. This licensing deal empowers Altesa to develop and commercialize Vapendavir, which has shown promise in treating infections like human rhinovirus and hand, foot, and mouth disease. Vaxart, focused on oral vaccines, views this collaboration as a way to boost value while addressing global health challenges.

Vaxart, a clinical-stage biotechnology company, will be presenting at the SVB Leerink CybeRx Series: Vaccine Forum on June 21, 2021, from 1:00 to 1:50 PM Eastern Time. The presentation will be led by CEO Andrei Floroiu and CSO Sean Tucker. The forum will cover updates on COVID vaccine development and discussions about future vaccines for various respiratory pathogens. Attendees can contact their SVB Leerink representative for virtual one-on-one meetings with Vaxart during the conference.

Vaxart, a clinical-stage biotechnology company, will present at the Jefferies Virtual Healthcare Conference on June 4, 2021. CEO Andrei Floroiu and CSO Sean Tucker will discuss the company's innovative oral recombinant vaccines. The presentation is scheduled for 1:30 PM Eastern Time and will last until 1:55 PM. Investors can schedule virtual one-on-one meetings during the conference. Vaxart focuses on developing oral tablets for various vaccines, including those for coronavirus and norovirus, aiming to streamline vaccine administration.

Vaxart, Inc. (Nasdaq: VXRT) has initiated a Phase 1b trial assessing its oral norovirus vaccine in elderly participants aged 55 to 80. This first subject enrollment marks a significant step in addressing the lack of approved vaccines for norovirus, which causes considerable illness and deaths annually among older adults. The study aims to evaluate safety and immunogenicity, with results expected to inform future COVID-19 vaccine development. Norovirus is responsible for 56,000 to 71,000 hospitalizations and 570 to 800 deaths each year in the U.S., with a substantial economic burden of $10.5 billion.

Vaxart (Nasdaq: VXRT) has initiated a Phase 1b trial for its norovirus oral vaccine candidate, enrolling the first subject. This study aims to assess various dosing regimens' safety and immunogenicity. Norovirus causes approximately 15% of U.S. children under five to fall ill annually, resulting in a $10.5 billion economic burden. The trial design includes 30 subjects aged 18-55, divided into three cohorts, focusing on optimal booster timing. Results may also influence Vaxart's COVID-19 oral vaccine program, entering Phase 2 trials mid-year.

Vaxart (Nasdaq: VXRT) announced positive results from its Phase I COVID-19 vaccine trial, highlighting that its oral vaccine candidate, VXA-CoV2-1, induces higher CD8⁺ T-cell responses compared to the Moderna and Pfizer vaccines. The vaccine induces mucosal immunity and shows cross-reactivity against various coronaviruses.

CEO Andrei Floroiu emphasized the potential benefits of these immune responses, while Chief Scientific Officer Dr. Sean Tucker noted their importance in fighting severe infections. The study's comparative data suggests Vaxart's vaccine may offer unique advantages against evolving variants.

Vaxart, Inc. (Nasdaq: VXRT) announced its progress on three oral tablet COVID-19 vaccine candidates, advancing VXA-CoV2-1 to Phase II and two S-only constructs to Phase I/II. The company aims to start four clinical trials for its oral norovirus vaccine in 2021. As of March 31, 2021, Vaxart reported cash equivalents of $177.3 million, a rise from $126.9 million at the end of 2020. However, the company faced a net loss of $16.0 million in Q1 2021, with revenue dropping to $506,000, primarily due to reduced royalty revenue.

Vaxart (Nasdaq: VXRT) announced that its founder and chief scientific officer, Sean Tucker, Ph.D., will present at the virtual World Vaccine Congress from May 4-6, 2021. The presentation, titled Vaxart oral COVID-19 vaccine; hold the ice and the needles, focuses on the company’s innovative oral tablet vaccine designed to combat COVID-19 without refrigeration. This congress is a premier event covering the entire vaccine value chain, highlighting scientific advancements and collaborations.